Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

No Evidence to Support Widespread Use of Fourth COVID Shot, Say EU Agencies

EU health agencies said on Wednesday there was no evidence to support the use of a fourth dose of COVID-19 vaccines developed by Pfizer and Moderna in the general population, but they recommend a second booster for people aged 80 and above. There is no clear evidence in the European…

Asharq Al-Awsat

New Covid antibody rates, how vaccine works, immunity – and how long you’re protected for

As Covid infection rates remain high across the country and people continue to lose their lives, we take a look at how the vaccines work, antibody levels across the UK and how quickly protection drops off

Daily Mirror

Second booster shields elderly from COVID but protection wanes quickly - study

A fourth dose of the Pfizer/BioNTech vaccine lowered rates of COVID-19 among the elderly but the protection against infection appeared short-lived, a large study in Israel has found.

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

Future of COVID boosters comes down to crucial meeting of FDA Advisers

An all-star panel of COVID-19 experts will convene this week to hash out how and when vaccines should be updated to address future variants as the virus continues to rapidly mutate.

Tribune News Service

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

CDC Says Heart Inflammation Risk Higher After COVID-19 Infection Than mRNA Vaccines: CNBC

According to a study published by the Centers for Disease Control and Prevention, myocarditis, pericarditis, and multisystem inflammatory syndrome w

Benzinga

Looking At Pfizer's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 10 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

‘The danger is still there’: As omicron lurks, native Americans are wary of boosters

When COVID-19 vaccines first became available, Native Americans acted swiftly and with determination to get their shots — as though they had everything to lose.

Tribune News Service

China promotes traditional cures as Pfizer pill alternatives

As Hong Kong’s outbreak became the deadliest in the world, among the aid Beijing sent to the financial hub were 1 million packets of honeysuckle, rhubarb root, sweet wormwood herb and other natural ingredients, all mixed according to principles of traditional Chinese medicine.

Tribune News Service

Anti-vax: COVID vax causes AIDS

Right-wing anti-vax activist Dr. Sherri Tenpenny was ridiculed for her statements

Salon

Covid vaccine slots open for children aged five to 11 in England

Parents and other carers now able to book lower-dose appointments for Monday onwards

The Guardian - UK

The Guide #28: The winners and losers of ‘slapgate’

In this week’s newsletter: after days of bad tweets and red carpet reactions, here’s the last word on the biggest Oscars moment of the decade

The Guardian - UK

Pfizer/BioNTech's COVID- Vaccine Cuts Hospitalization Risk In Kids Aged 5-11 Years: Reuters

According to a US-based study, children ages 5 to 11 who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine were 68% less likely to be hospitalized during the omicron wave than unvaccinated children. Adolescents aged 12-18 who received two shots of the vaccine were around 40% less likely to be hospitalized with the…

Benzinga

Opinion: In Crisis Mode, Shanghai Should Stick to Zero-Covid Approach

A UCLA professor’s long-term coexistence plan won’t help and could hinder Shanghai’s response to the current crisis, a Zhejiang University professor argues

Caixin Global

Get all your
news in one place.

100's of premium titles.
One news app.

Reuters

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Axios

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Salon

FDA approves second shot for 50+

The authorization for another booster arrives just as BA.2 becomes the dominant strain in the U.S.

Caixin Global

Opinion: How Shanghai Can Pioneer a New Path for Disease Control

Amid worst Covid-19 outbreak, city could turn pandemic into manageable endemic disease using self-isolation, self-testing and advanced drugs and vaccines

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Who really needs a second COVID booster? Here's what to know

Many Americans can now get a second COVID-19 booster, but it’s hard to tell who really needs another shot right now and who could wait

Benzinga

Why BioNTech Shares Are Surging Today

BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…

The Conversation

COVID-19 vaccines for the youngest children may be inching closer to authorization – a pediatrician explains how they're being tested

For some parents of young children, the wait for COVID-19 vaccines has been long and agonizing.

The Independent UK

BioNTech's quarterly profit soars on COVID-19 vaccine demand

BioNTech has reported another quarter of strong earnings growth

Chicago Tribune

Commentary: There is much we still don’t know about giving 5- to 11-year-olds a COVID-19 vaccine

Should children ages 5 to 11 receive the COVID-19 vaccine? This is a difficult question without an easy answer, something you wouldn’t know from the strident opinions of politicians and health experts.

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Los Angeles Times

Infectious omicron BA.2 now dominant in US, with coronavirus spring rise likely

LOS ANGELES — The highly infectious BA.2 omicron subvariant is now the dominant version of the coronavirus circulating in the United States, according to federal estimates, a development that is triggering fresh concerns of a potential springtime wave.

1 … 58 59 60 61

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.